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Onabotul inum toxin (BoNT-A) is considered the standard of care for the focal management of hypertonicity in children. 1 In a joint position paper from the American Academy of Neurology and the Child Neurology Society in 2010, BoNT-A was considered a safe, effective treatment of focal spasticity and dystonia in children with cerebral palsy (CP). 2 However, the decreased responsiveness to BoNT-A with repeated dosing in some children with CP has resulted in providers using rimabotulinum toxin (BoNT-B), despite limited evidence supporting its use for spasticity management in this group. 2, 3 With regard to the use of BoNT-B in adults with cervical dystonia and BoNT-A in secondary nonresponse, some individuals rapidly develop nonresponse to BoNT-B. 4, 5 This is also a potential concern for children with CP. In a pilot study of 29 children, functional improvements lagged in the children receiving BoNT-B who had a secondary nonresponse to BoNT-A. 3 Although this was suggestive of decreased efficacy, identification of nonresponse to BoNT-B was not done. Therefore, understanding the responsiveness to and the effectiveness of BoNT-B in children with CP who have nonresponse to BoNT-A is necessary to evaluate the benefit of BoNT-B treatment of focal spasticity management in this group.
Both the benefits of BoNT-B and the safety of its use in children with CP have not been thoroughly evaluated. In adults with cervical dystonia, the increased incidence of adverse effects (AEs) ranges from 0% to 89%, with most studies showing the incidence 6Y9 to be greater than 50%. Currently, all botulinum toxins approved by the United States Food and Drug Administration have a boxed warning regarding the potential for spread to noninjected muscles, based on AE reports, including one randomized study involving BoNT-A use in children with CP that reported a death. 10 The overall incidence of AEs with BoNT-A in children with CP 11, 12 ranges from 6.2% to 10%. A recent study evaluating potential factors contributing to the development of AEs of BoNT-A injections in children with CP found that those with greater medical fragility and Gross Motor Function Classification System (GMFCS) level IV or V had an increased incidence of AEs. 11 The incidence of AEs in children receiving BoNT-B seems to be greater than that for BoNT-A, with two studies showing AEs at 24.2% (15/62 injection sessions) 3 and 28.6% (2/7 individuals). 13 However, these studies had limited numbers of individuals and did not include evaluation of the potential risk factors of susceptibility to AEs. A third study evaluating botulinum neurotoxin use in children with CP found the incidence of AEs to be 6.8% (51/748), although few children received BoNT-B injections. 14 Further evaluation of AEs with the use of BoNT-B in children with CP, particularly with regard to potential risk factors of AEs, is needed to further one's understanding of the safety of this intervention in these children.
At the authors' institution, BoNT-A and phenol neurolysis are used to manage focal hypertonicity in children with CP. The use of BoNT-B for focal hypertonicity management in children with CP was initiated in March 2001 and discontinued in August 2002 because of concern regarding AEs. However, interest in reinstating the use of BoNT-B has remained high, prompting further review and analysis of this treatment. Herein, the authors report their experience with the use of BoNT-B for the management of focal hypertonicity (defined as spasticity, dystonia, or both) in children with CP.
METHODS
After approval of this study by the University of Minnesota Institutional Review Board, a retrospective review was conducted of medical records for patients treated between March 16, 2001 , and August 2, 2002. All patients and/or their legally authorized representatives had previously agreed to allow the use of the patients' records for research; individual consent was therefore not required by the institutional review board for this study. The inclusion criteria were as follows: a diagnosis of CP; age younger than 18 yrs at the time of the first injection; and at least one BoNT-B injection. The exclusion criterion was lack of consent to use the patient's medical records for research.
A search of the institution's medical records was conducted using a computerized document management system with the keywords Myobloc (Solstice Neurosciences Inc, South San Francisco, CA) and botulinum toxin B. Abstracted information included the child's name, medical record number, date of birth, sex, type of CP (hemiplegic, diplegic, triplegic, or quadriplegic), tone type (spasticity, spasticity and dystonia, or dystonia), GMFCS level (either in the medical record or determined upon review of information provided in the record at or near the time of the initial injection), other medical diagnoses, previous use of BoNT-A, and development of clinical resistance to BoNT-A. Clinical resistance was defined as decreasing effectiveness or reduced duration of response at the same or an increased dosage. Response to injections was based on family perceptions of the child's function, daily care, and physical examination. There was no single standardized method of reporting of the response to injections, with one or more of the previously mentioned elements used to determine response. In the individuals with minimal or no response, further injections were not performed. For each BoNT-B injection episode, data were abstracted that included the identity of the healthcare provider performing the injections, the child's weight, the dose of BoNT-B, the dose and dilution of BoNT-A (if concurrently used), the dose of phenol (if concurrently used), the muscles injected, the clinical setting for injections, and the self-reported or parent-/guardian-reported AEs at follow-up. AEs were determined either by openended or directed questioning at the clinic visit or by telephone follow-up. An injection episode was defined as all injections a child received in a single clinical encounter.
Descriptive statistics were used for age, weight, type of CP, tone type, GMFCS level, BoNT-B dosing, BoNT-A dosing, phenol dosing, AEs, and perceived effects of injections. The Pearson W 2 test was used to evaluate differences in AEs regarding type of CP, tone type, GMFCS level (I/II, III, or IV/ V), location of injections (upper extremities, lower extremities, or both), medical fragility (defined as having a gastrostomy tube and/or seizures), provider performing the injection, setting in which the injections were performed (clinic, operating room, or rural clinic), reported benefit from injections as reported by the patient or the caregiver and physician, number of muscles injected (1Y2, 3Y4, or Q5), use of lowdose (G10,000 U) vs. high-dose (Q10,000 U) BoNT-B, and concomitant use of BoNT-A and/or phenol. Differences between the patients who received one episode of injections and those who received two or more episodes were evaluated using the McNemar test.
RESULTS
Between March 2001 and August 2002, a total of 82 children with a diagnosis of CP underwent 116 episodes of injections with BoNT-B (Table 1) . Of the 82 children, 61 (74%) had secondary nonresponse to BoNT-A, 18 (22%) had no previous exposure to BoNT-A or lacked documentation regarding BoNT-A exposure, and 3 (4%) had AEs with BoNT-A injections. Overall, of the 82 children, 60 participated in one episode of injections, 13 had two episodes, 7 had three episodes, 1 had four episodes, and 1 had five episodes ( Table 2) . With regard to BoNT-B, the mean dose was 8,959 U (range, 3,000Y22,000 U) and the mean units per kilogram dose was 343.4 U/kg (range, 73.7Y657.9 U/kg). The number of muscles injected with BoNT-B in an individual subject in a single injection episode ranged from 1 to 10. For the first episode of injections, 67 subjects (81.7%) Values are presented as number (percentage) unless otherwise indicated. a Percentages total greater than 100% because of rounding.
had BoNT-B; 9 (11.0%) had BoNT-B and phenol; 4 had both BoNT-A and BoNT-B; and 2 had BoNT-A, BoNT-B, and phenol. After the first episode of injections, 12 (16.9%) of the 71 children for whom AE data were available experienced no or minimal tone reduction. Five children had nonresponse after the second injection episode. For all injection episodes, 19 (26.8%) children had no or minimal response. In 17 (89.5%) of these 19 children, secondary nonresponse to BoNT-A had been reported. No significant differences were found between responsiveness of the subjects who had no or minimal benefit from the first episode of injections and the presence or absence of previous BoNT-A exposure (P = 0.67). Of the 116 injection episodes, 74 episodes (63.8%) had documented reports of response from both the parent/guardian or the patient and the physician. Agreement with regard to response to the injections occurred in 65 (87.8%) of 74 of these injection episodes.
For all children, reported AEs included bowel function changes (constipation or diarrhea), urinary changes (retention or incontinence), dry mouth, new or increased difficulties with oral motor function (chewing/swallowing/drooling), new or increased frequency of seizures, generalized weakness or hypotonia, visual disturbances, and nausea (Table 3) . Reports concerning AEs after the first episode of injections were available for 71 children (86.6%). Of these 71 children, 48 (67.6%) had no AEs, 16 (22.5%) had 1 AE, 5 (7.0%) had 2 AEs, and 2 (2.8%) had 3 AEs, for a total of 32 AEs experienced by 23 children (32.4%). With respect to the two children who had Values are presented as number (percentage) unless otherwise indicated.
www.ajpmr.com three AEs, BoNT-B was administered to both the upper and lower extremities: one child received injections to the right arm and the right leg and one child received injections to both arms and both legs. For those with nonresponse to the first injection episode, 1 (8.3%) of 12 children experienced an AE (dry mouth). Of all 19 children with report of nonresponse to injections, 3 experienced AEs (3/19 [15. 8%]), with 2 experiencing dry mouth and 1 having a new-onset seizure (after the fifth injection episode). No significant differences were noted in AEs related to response to injections (P = 0.09), GMFCS level (P = 0.53), type of CP (P = 0.99), or muscle tone (P = 0.94); degree of medical fragility (P = 0.90); injection site (P = 0.26); number of muscles injected (P = 0.87); healthcare provider performing the injection (P = 0.10); medical setting in which the injection was performed (P = 0.74); high-dose vs. low-dose BoNT-B (P = 0.18); or concomitant use of BoNT-A and/or phenol (P = 0.92).
No AE was severe enough to require hospitalization. For all 116 injection episodes, documentation of the presence or the absence of AEs was identified in 104 episodes (89.7%). Of these 104 episodes with documentation, 31 (29.8%) had AEs. No significant difference was found in the AEs between the patients who had one episode of injections and the patients who had a second episode of injections (P = 0.84). Further statistical analysis of the subsequent injection episodes was not performed because of the small numbers of patients who received more than two episodes of injections.
BoNT-B injections is challenging to determine. Seizures have not been reported in adults with cervical dystonia receiving BoNT-B. Reports of seizures as related to AEs are mixed in children with CP receiving BoNT-A injections. 10, 18, 19 The mechanism behind the association between seizures and both BoNT-A and BoNT-B injections is unknown and may be more reflective of predisposition to seizures caused by the underlying brain abnormality in these children than of an association with the injections. Clearly, further research and evaluation are needed in this area.
The authors also found no significant difference in AEs by degree of medical fragility, GMFCS level, or dose of BoNT-B. Detecting these differences with 80% power would have required approximately 7960, 178, and 417 children in each group, respectively. Although these results stand in contradistinction to those in a 2010 report by Naidu et al. regarding the use of BoNT-A in children with CP, this difference may be a result of the number of children in this study. In the Naidu et al. study, 11 1147 children with CP received BoNT-A injections. In addition, the relatively high incidence of AEs experienced by the children in this study may have masked small differences with regard to medical fragility, GMFCS level, or dosing. It seems that in children with CP, AEs from BoNT-B injections may not be predictable by medical fragility, GMFCS level, or BoNT-B dosing. Larger prospective studies to evaluate this would be beneficial. Recommendations for altering the dosing of BoNT-B on the basis of medical fragility or GMFCS level cannot be made and should be based on the individual needs of the patient and the muscles targeted.
In the patients in this study, AEs were not associated with the concurrent use of BoNT-A and/or phenol. The authors believe that this study is the first to show the simultaneous use of different types of botulinum toxins in children with CP. In children with CP, the use of two different types of botulinum neurotoxins may allow more muscles to be injected during an injection episode, or it may allow the same number of muscles to be injected but with a lower dose of each botulinum toxin. Further research is needed about these potential injection options and outcomes. In addition, there is little information available about adjusting botulinum toxin dosing on the basis of the concurrent use of other botulinum toxins or with other spasticity management regimens. Because only a few children in this study received both BoNT-B and BoNT-A during a single injection episode, the authors were not able to perform further statistical analysis on dosing and AEs in those receiving both neurotoxins in the same injection episode.
